Driven by both industry and capital, Xi Venture Capital and Zhaoyan New Drugs have partnered to establish a biopharmaceutical fund and complete multiple project investments
Recently, Wuxi Jinyifu New Biopharmaceutical Venture Capital Partnership Enterprise (Limited Partnership) (hereinafter referred to as "Wuxi Jinyifu New Biopharmaceutical Fund"), established in cooperation with CRO safety evaluation leading enterprise Zhaoyan New Drug, has completed investments in a number of projects including Xingji Biology, Xuanjing Biology, Kangyuan Bochuang, etc. The funds will be used to support the research and development of the enterprise's core pipeline and the construction of related innovative technology platforms. In 2024, Xichuang Capital, Zhaoyan New Drugs, and Huishan Science and Technology Innovation Group signed a framework cooperation agreement to carry out in-depth cooperation in the form of "1+1+N", namely landing on "one platform", establishing "one fund", and introducing "N projects", jointly establishing the Wuxi Jinyifu New Biomedical Fund with a target scale of 5 billion yuan, to support and promote the research and industrialization process of synthetic biology, medical devices, future food and other fields with "patient capital". The landing of multiple projects this time is a vivid practice of Xi Venture Capital deepening the "industry investment linkage", introducing Zhaoyan New Drug and its upstream and downstream enterprises in the industry chain into Wuxi through equity investment, and achieving deep integration of capital, technology, and ecology. Xi Venture Capital has precisely laid out the innovation track of the biopharmaceutical industry, accelerating the transformation of innovative technological achievements with capital power, and empowering Wuxi's future high-quality development of the health industry.
Wuxi Jinyifu New Biopharmaceutical Fund and Huahai Pharmaceutical jointly participated in Xingji Biotechnology's A+round financing with a total amount of nearly 100 million yuan. Rehabilitation capital and Pharmares continue to contribute, and the funds are mainly used to promote key projects such as Phase II clinical research of Xingji Biotechnology's core pipeline. Xingji Biotechnology was established in June 2020, jointly founded by Rehabilitation Capital and a team of scientists. It focuses on the research and development of anti infective macromolecular drugs (antibody drugs, long-acting fusion protein drugs, etc.), aiming to overcome clinical challenges that are difficult to solve with high mortality rates of drug-resistant bacteria, fungal/viral infections, and traditional antibiotics. It provides innovative treatment solutions for severe infections and plays a key role in the life-threatening anti infective field.
Wuxi Jinyifu New Biopharmaceutical Fund has completed the first round of Pre-A financing for Xuanjing Biotechnology. The funds will mainly be used to rapidly promote the clinical research of core product RG002C0106, as well as the continuous development of extrahepatic delivery technology and drug pipelines, helping the enterprise accelerate its global technology layout.
Xuanjing Biotechnology was founded in 2022, relying on its independent intellectual property development technology platform for three types of nucleic acid drugs - RIHOST ® (Design screening techniques) RICMO ® (Chemical Modification Technology) and LICOD ® (In vivo delivery technology) has broken through key technological bottlenecks in the industry, achieved a multidimensional technological layout from liver targeting to non liver tissue delivery, and made multiple breakthroughs. The company's initial pipeline has excellent development potential for high-risk indications and multiple rare diseases with outstanding unmet clinical needs. It is about to launch phase II clinical research and is expected to become the best in class and the first globally marketed siRNA drug targeting C3. At the same time, the company has established various globally implementable extrahepatic tissue delivery technologies, especially renal tissue delivery technology, which is at the forefront of the world.
Wuxi Jinyifu New Biopharmaceutical Fund participated in the B-round financing of Kangyuan Bochuang with a total amount of over 100 million yuan. The funds will mainly be used to strengthen the construction of technology platforms (such as genetic engineering cell banks, GPCR antibody discovery technology) and expand global cooperation, accelerating the innovation process of new drug research and development services.
Kangyuan Bochuang was founded in 2017 and is an innovative biotechnology company focused on the research and development of bispecific/multispecific antibodies. The company has developed a series of differentiated product pipelines with dual antibody and multi antibody as the core, focusing on "FIC" and "BIC" therapies in oncology and autoimmune diseases. It also provides antibody discovery services to global new drug research and development enterprises through its proprietary platform technology. The company has a rich R&D pipeline and is located in the domestic clinical stage of the tertiary antibody project targeting the multiple myeloma market. It is a global shallow FIC or BIC drug and was included in Pfizer's Ignite global development plan in November 2024. It obtained FDA IND approval in December 2024 and is expected to apply for breakthrough treatment in the second half of this year.
